Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123 CAR-T Cell Therapy for R/R AML
NCT04265963Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Chongqing Precision Biotech. Primary endpoints: Adverse events related to treatment at 2 years and Response rate of CD123 CAR-T treatment at 2 years. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04265963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265963.